Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16277326 | 0.86 | KMT2A (0.38) | KMT2AMEN1TDP1L3MBTL1METAP2 | |
| SCHEMBL10595950 | 0.85 | TDP1 (0.42) | KMT2AMEN1TDP1L3MBTL1NOTUM | |
| SCHEMBL16277310 | 0.83 | CES2 (0.41) | TDP1KDM4E | |
| SCHEMBL19585479 | 0.81 | KMT2A (0.40) | KMT2AMEN1TDP1L3MBTL1METAP2 | |
| SCHEMBL1867302 | 0.79 | CA12 (0.41) | KMT2AMEN1TDP1NOTUMCYP3A4 | |
| SCHEMBL20780583 | 0.79 | MEN1 (0.42) | KMT2AMEN1TDP1L3MBTL1METAP2 | |
| SCHEMBL19242268 | 0.79 | FABP3 (0.42) | KMT2AMEN1TDP1L3MBTL1METAP2 | |
| SCHEMBL27661072 | 0.78 | HAAO (0.41) | KMT2ATDP1L3MBTL1NOTUMCYP3A4 | |
| SCHEMBL14352560 | 0.77 | CA12 (0.47) | KMT2AMEN1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL3642705 | 0.76 | KMT2A (0.38) | KMT2AMEN1TDP1L3MBTL1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024088069-A1 | PREPARATION FOR AROMATIC KRAS MUTANT PROTEIN INHIBITOR AND USE THEREOF | 药雅科技(上海)有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-117903192-A | Preparation method of 3-methoxy isoquinoline compound intermediate | 上海相辉医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117263959-A | Preparation and application of aromatic KRAS mutant protein inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| EP-2921480-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921480-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014077401-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2014-05-22 | — | — | WO | disclosed |
| EP-2726479-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT LABORATORIES (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2013000994-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | KMT2A 1292/4885MEN1 2624/4885TDP1 948/4885 |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | KMT2A 1580/4885MEN1 2237/4885TDP1 3959/4885 |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | KMT2A 737/4885MEN1 4110/4885TDP1 33/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | KMT2A 1292/4885MEN1 2624/4885TDP1 948/4885 |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | KMT2A 737/4885MEN1 4110/4885TDP1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.